This excerpt taken from the AGN DEF 14A filed Mar 19, 2009.
Allergans use of the LD50 test warrants attention from management and shareholders for several reasons:
Given the seriousness of the issue, Allergan should protect the Company and its shareholders by providing updates on its efforts to replace the LD50 test. The National Research Council forecasts that, within a generation, new methods will greatly reduce, if not eliminate, all animal testing. Eliminating LD50 testing should be a priority in this process.